Skip to main content
profile image
Selected Works of Achal Achrol, MD
Article
MDNA55: A locally administered IL4 guided toxin as a targeted treatment for recurrent glioblastoma.
Journal of Clinical Oncology (2019)
  • Dina Randazzo, Duke University
  • Achal Achrol, Pacific Neuroscience Institute and John Wayne Cancer Institute at Providence, Saint John’s Health Center, Santa Monica, CA;
  • Manish K. Aghi, University of California, San Francisco
  • Martin Bexon, Medicenna Biopharma, Houston, TX;
  • Steven Brem, University of Pennsylvania
  • Andrew Jacob Brenner, University of Texas Health Science Center at San Antonio
  • Nicholas A. Butowski, University of California, San Francisco
  • Chandtip Chandhasin, Medicenna Biopharma, Houston, TX;
  • Sajeel A. Chowdhary, Florida Hosp Cancer Inst, Orlando, FL;
  • Melissa Coello, Medicenna Biopharma, Houston, TX;
  • John Floyd, University of Texas Health Science Center at San Antonio
  • Santosh Kesari, University of California, San Diego
  • Fahar Merchant, Medicenna Biopharma, Houston, TX;
  • Nina Merchant, Medicenna Biopharma, Houston, TX;
  • Michael A. Vogelbaum, Cleveland Clinic
  • Frank D Vrionis, H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL;
  • Miroslaw Zabek, Mazovian Brodnowski Hospital, Warsaw, Poland;
  • John H. Sampson, Duke University
Link
Disciplines
Publication Date
May 20, 2019
DOI
10.1200/JCO.2019.37.15_SUPPL.2039
Citation Information
Dina Randazzo, Achal Achrol, Manish K. Aghi, Martin Bexon, et al.. "MDNA55: A locally administered IL4 guided toxin as a targeted treatment for recurrent glioblastoma." Journal of Clinical Oncology Vol. 37 (2019) p. 2039 - 2039
Available at: http://works.bepress.com/achalsingh-achrol/65/